RecruitingNCT07482176
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
PHASE3 · 534 planned enrolment
- Countries listed
- 1
- Registry update
- September 24, 2026
immortal.lifePublic trial registrations naming Adverum Biotechnologies, Inc. as an industry lead sponsor.
This is an independent registry-name view, not a verified corporate profile, portfolio valuation, ownership map, endorsement, or investment recommendation.
This does not mean that no transaction exists. A record appears only after its disclosure source and the connection to this exact registry sponsor identity are separately verified.
PHASE3 · 534 planned enrolment